Compass Planning Associates Inc Invests $37,000 in Moderna, Inc. (NASDAQ:MRNA)

Compass Planning Associates Inc purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 900 shares of the company’s stock, valued at approximately $37,000.

Several other institutional investors have also recently added to or reduced their stakes in MRNA. Wilmington Savings Fund Society FSB grew its holdings in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the last quarter. Venturi Wealth Management LLC lifted its position in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after acquiring an additional 389 shares during the last quarter. Blue Trust Inc. increased its position in Moderna by 53.1% in the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after acquiring an additional 388 shares in the last quarter. Finally, EMC Capital Management raised its stake in shares of Moderna by 311.2% in the fourth quarter. EMC Capital Management now owns 1,250 shares of the company’s stock worth $52,000 after acquiring an additional 946 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders sold 2,664 shares of company stock worth $115,210. Corporate insiders own 15.70% of the company’s stock.

Moderna Price Performance

Shares of MRNA stock opened at $33.73 on Friday. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47. The firm has a fifty day moving average of $38.17 and a 200-day moving average of $53.20.

Analyst Upgrades and Downgrades

MRNA has been the topic of several research analyst reports. Berenberg Bank increased their price target on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Evercore ISI dropped their target price on Moderna from $60.00 to $50.00 and set an “in-line” rating for the company in a research report on Monday, January 27th. JPMorgan Chase & Co. reduced their target price on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research note on Tuesday, November 26th. Finally, Barclays downgraded shares of Moderna from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $111.00 to $45.00 in a research note on Tuesday. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.